<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">TCM</journal-id><journal-title-group><journal-title>Traditional Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">2166-6067</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/TCM.2019.82021</article-id><article-id pub-id-type="publisher-id">TCM-29132</article-id><article-categories><subj-group subj-group-type="heading"><subject>TCM20190200000_65582922.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  中医药在以肺磨玻璃结节为特征的早期肺癌中应用进展
  Progress in the Application of Traditional Chinese Medicine in Early Stage Lung Cancer Characterized by Pulmonary Ground Glass Nodules
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>肖</surname><given-names>晓宇</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>焦</surname><given-names>丽静</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>惠民</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>许</surname><given-names>玲</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>上海交通大学附属新华医院，上海</addr-line></aff><aff id="aff1"><addr-line>上海中医药大学附属岳阳中西医结合医院，上海</addr-line></aff><aff id="aff2"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>12</day><month>02</month><year>2019</year></pub-date><volume>08</volume><issue>02</issue><fpage>111</fpage><lpage>119</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   肺磨玻璃结节(Ground-Glass Nodule, GGN)，作为早期肺癌的非特异性影像学表现，具有恶性率高、遗传异质性突出、治疗对策难的特点。而GGN的长期随访检测，为中医药发挥治未病的特色提供了可能。本文梳理GGN的遗传学特征、研究现状，重点探讨了中医药在肺癌发生预防中的临床疗效及作用机制应用研究进展，以期为今后中医药在以GGN为特征的早期肺癌的临床防治及研究提供思路。 Ground-glass nodule (GGN), as a non-specific imaging manifestation of early stage lung cancer, has the characteristics of high malignancy, prominent genetic heterogeneity, and difficult treatment strategies. For the long-term follow-up test of GGN, it is possible to play the role of “prevention of disease” for the treatment of traditional Chinese medicine. This paper reviews the genetic characteristics and research status of GGN, and focuses on the application of traditional Chinese medicine in the prevention and treatment of lung cancer. The aim is to provide ideas for early-stage lung cancer characterized by GGN. 
  
 
</p></abstract><kwd-group><kwd>肺磨玻璃结节，肺癌，预防，中医药，癌变, 肺磨玻璃结节，肺癌，预防，中医药，癌变</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>中医药在以肺磨玻璃结节为特征的早期肺癌中应用进展<sup> </sup></title><p>肖晓宇<sup>1</sup>，焦丽静<sup>1</sup>，李惠民<sup>2</sup>，许玲<sup>1*</sup></p><p><sup>1</sup>上海中医药大学附属岳阳中西医结合医院，上海</p><p><sup>2</sup>上海交通大学附属新华医院，上海</p><p><img src="//html.hanspub.org/file/8-2270402x1_hanspub.png" /></p><p>收稿日期：2019年2月15日；录用日期：2019年2月28日；发布日期：2019年3月6日</p><disp-formula id="hanspub.29132-formula49"><graphic xlink:href="//html.hanspub.org/file/8-2270402x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>肺磨玻璃结节(Ground-Glass Nodule, GGN)，作为早期肺癌的非特异性影像学表现，具有恶性率高、遗传异质性突出、治疗对策难的特点。而GGN的长期随访检测，为中医药发挥治未病的特色提供了可能。本文梳理GGN的遗传学特征、研究现状，重点探讨了中医药在肺癌发生预防中的临床疗效及作用机制应用研究进展，以期为今后中医药在以GGN为特征的早期肺癌的临床防治及研究提供思路。</p><p>关键词 :肺磨玻璃结节，肺癌，预防，中医药，癌变</p><disp-formula id="hanspub.29132-formula50"><graphic xlink:href="//html.hanspub.org/file/8-2270402x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/8-2270402x8_hanspub.png" /> <img src="//html.hanspub.org/file/8-2270402x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>肺癌是癌症死亡的首要原因 [<xref ref-type="bibr" rid="hanspub.29132-ref1">1</xref>]。肺癌患者起病隐匿，能通过手术切除治疗的不足25% [<xref ref-type="bibr" rid="hanspub.29132-ref2">2</xref>]。近年来，随着低剂量螺旋CT在早期体检筛查中的应用，越来越多表现为GGN的早期肺癌被诊断出来。虽然这些GGN通常无淋巴结或血液转移，其术后5年生存率接近100% [<xref ref-type="bibr" rid="hanspub.29132-ref3">3</xref>]，但对于和单发GGN有不同临床和遗传学特征的多发GGN来说，临床治疗仍缺乏良策。因此，对GGN进行准确评估，降低误诊率，采取合理管理办法，将肺癌治疗关口前移，是提高肺癌防治水平进而提升肺癌总体生存率的有效措施。本文梳理了GGN的遗传学特征、研究现状，重点论述中医药在肺癌发生预防中临床疗效及作用机制的应用研究进展，以期为今后中医药在以GGN为特征的早期肺癌的临床防治及研究提供思路。</p></sec><sec id="s4"><title>2. GGN的定义、分子遗传学特征及研究现状</title><p>GGO (Ground-Glass Opacity)，影像学上是指肺CT值轻度增加，但其内部的支气管和血管结构仍清晰可见，当造成肺内局限性或结节性改变时，则称为GGN。由于GGN早期筛查的隐匿性，目前尚无推荐的生物学标识。而现在多以CT影像上实性成分的比例来判断GGN的预后，研究显示，不含实性成分的纯磨玻璃结节(Pure Ground-Glass Noudle, pGGN)恶性率约18%，含实性成分的混合磨玻璃结节(Mixed Ground-Glass Noudle, mGGN)的恶性率则高达64% [<xref ref-type="bibr" rid="hanspub.29132-ref4">4</xref>]。除此以外，性别、吸烟以及肺癌家族史也是GGN的危险因素 [<xref ref-type="bibr" rid="hanspub.29132-ref5">5</xref>]。近年来，随着肺癌驱动基因谱的揭示，也为GGN的治疗提供了新的思路。mGGN比pGGN往往更易发生表皮生长因子受体(Epidermal Growth Factor Receptor, EGFR)突变 [<xref ref-type="bibr" rid="hanspub.29132-ref6">6</xref>]，原位腺癌、微侵袭性腺癌和浸润性腺癌的EGFR突变率分别为25.0%、29.0%和63.6% [<xref ref-type="bibr" rid="hanspub.29132-ref7">7</xref>]。与单发GGN不同，多发GGN的肺腺癌具有70.8% [<xref ref-type="bibr" rid="hanspub.29132-ref8">8</xref>] ~92% [<xref ref-type="bibr" rid="hanspub.29132-ref9">9</xref>] 的遗传异质性，提示多发GGN中多病灶驱动基因的突变可能是相互独立的，病变可能有不同的起源，可归因于肺呼吸性上皮细胞暴露于致癌物质中随后独立发生相似的肿瘤形态改变，但具有不同的克隆类型 [<xref ref-type="bibr" rid="hanspub.29132-ref8">8</xref>]。起源异质性的发现，使得我们不能对部位各异的GGN一概而论，也为治疗带来了新的难度。2017年Fleischner学会对偶发性肺GGN的管理建议 [<xref ref-type="bibr" rid="hanspub.29132-ref10">10</xref>] 中提出，有一定风险的结节多采用VATS亚肺叶切除的办法，而多发GGN的术后管理和单发GGN的随访管理方案尚无共识。</p></sec><sec id="s5"><title>3. 中医药在GGN治疗中可行性的探讨</title><p>GGN普遍呈惰性发展趋势，Chang等 [<xref ref-type="bibr" rid="hanspub.29132-ref11">11</xref>] 统计出91.7%的pGGN体积倍增时间(Volume Doubling Time, VDT) &gt; 400天，而mGGN的VDT显著缩短(457~538天) [<xref ref-type="bibr" rid="hanspub.29132-ref12">12</xref>]。pGGN发展为mGGN的平均时长是3.8 &#177; 2.0年 [<xref ref-type="bibr" rid="hanspub.29132-ref13">13</xref>]，因此GGN较长的VDT为临床随访提供了一定依据，也为中医药发挥未病防变，已病防传的治未病优势提供了可能。</p><sec id="s5_1"><title>3.1. 中药复方在肺癌发生中的疗效和作用</title><p>早在1995年欧阳琦进行的随机对照双盲试验，已发现保肺饮(臭牡丹、龙葵、桔梗、甘草)对肺癌患者癌前病变支气管上皮细胞重度增生有阻断和治疗作用，3年后肺癌发病率由干预前的89.47/10万下降为干预后的35.70/10万，下降2.51倍(P &lt; 0.05) [<xref ref-type="bibr" rid="hanspub.29132-ref14">14</xref>]。体内研究也显示，保肺饮干预19周可降低三甲基胆蒽(MCA)诱发的肺癌大鼠癌前病变程度，减少癌变动物癌周组织炎症，延缓大鼠体重下降 [<xref ref-type="bibr" rid="hanspub.29132-ref15">15</xref>]，其机制与下调肝细胞生长因子(Hepatocyte Growth Factor, HGF)表达，上调上皮标志分子E-cadherin表达，下调间质标志分子vimentin表达进而逆转上皮间质转化(Epithelial-Mesenchymal Transition, EMT)进程有关 [<xref ref-type="bibr" rid="hanspub.29132-ref16">16</xref>]。</p><p>鉴于目前肺部GGN的诊断尚不明确，对开展肺癌发生的中医药预防研究带来一些困难，而中医药多采用肺癌发生体内模型来进行预防作用机制的评价研究。肺为娇脏，不耐寒热，易至虚证，肺癌常表现为本虚标实，故治法多遵循扶正抑癌的治则，而滋阴益气被后世医家认为应贯彻肺癌治疗始终。现中医药复方对肺癌预防的体内研究治疗思路多集中在补益类和祛邪类中药，而滋阴类的经方和验方已被证实具有免疫调节、抗炎及抗氧化等作用，应用前景较好。</p><p>六味地黄丸是中医滋阴名方，具有滋补肝肾之阴，补先天之本的作用。而增殖细胞核抗原(Proliferating Cell Nuclear Antigen, PCMA)是真核细胞染色体DNA复制的必要成分，与肿瘤发生密切相关。研究证实六味地黄丸(1.17 g/kg/次)干预4周可抑制乌拉坦诱发小鼠肺肿瘤中炎症因子TNF-α的释放(P = 0.007)并下调PCNA的表达(P = 0.013)，从而延缓肺部肿瘤的发生 [<xref ref-type="bibr" rid="hanspub.29132-ref17">17</xref>]。在氨基甲酸乙酯所致小鼠肺腺癌模型中，六味地黄汤可降低肺癌的诱发率由80.0%至40.7% (P &lt; 0.05)，尤其是较对照组上调48.8%抑癌基因P53表达，并在“阴虚”类小鼠中表现得尤为明显 [<xref ref-type="bibr" rid="hanspub.29132-ref18">18</xref>]。同时，郭慧君等发现六味地黄丸对小鼠肺肿瘤的预防作用(治疗组vs对照组诱发率：分别为18.2%、63.6%)与其脾指数、巨噬细胞活性增高显著相关(P &lt; 0.05) [<xref ref-type="bibr" rid="hanspub.29132-ref19">19</xref>]。而具有养阴润肺功效的二冬膏 [<xref ref-type="bibr" rid="hanspub.29132-ref20">20</xref>] 在乌拉坦诱导小鼠肺肿瘤模型中能使肺肿瘤发生率从86.7%降至40.0%~66.7%，平均肿瘤结节数从7.32降至3.97~5.53，同时显著降低血清中TNF-α、IL-10含量(P &lt; 0.01)和肺组织中TGF-β1含量和活性表达(P &lt; 0.05)。清金保肺主治气阴两伤证的清燥救肺汤 [<xref ref-type="bibr" rid="hanspub.29132-ref21">21</xref>] (8.4, 16.8, 33.6 g/kg)可使乌拉坦诱发小鼠肺肿瘤发生率从91.7%降至58.3%~75.0%，平均肿瘤结节数从5降至3 (P &lt; 0.05)，同时显著降低肺癌组织中TGF-β1、Smad2和p38丝裂原活化蛋白激酶通路(p38 MAPK)蛋白的活性和表达(P &lt; 0.05)。</p><p>《难经》早云：“积者，阴气也”，历代亦不乏论述温阳法在积证治疗中发挥的重要作用，如清代王旭高提出：“积聚之证，大抵寒多热少，虚多实少，桂枝、肉桂、附子、吴茱萸为积聚之要药”，提示温阳治法在积证治疗中的重要作用。现代研究较多的温阳方阳和汤 [<xref ref-type="bibr" rid="hanspub.29132-ref22">22</xref>] 在乌拉坦诱发小鼠肺肿瘤干预12周后与模型组相比小鼠血清中超氧化歧化酶(Superoxide Dismutase, SOD) (P &lt; 0.05)，过氧化氢酶(Catalase, CAT) (P &lt; 0.05)的活性及IL-2 (P &lt; 0.05)与TNF-α (P &lt; 0.01)含量上升，并抑制与癌变相应的谷胱甘肽-S转移酶(Glutathione S-Transferases, GST)活性(P &lt; 0.01)及丙二醛(Malondialdehyde, MDA)含量(P &lt; 0.05)增高。用药18周，模型组与阳和汤组肿瘤发生率分别为90%、40%，肿瘤个数分别为5.4 &#177; 1.5、2.8 &#177; 1.5 (P &lt; 0.05)，肿瘤大小分别为15.6 &#177; 2.4mm<sup>2</sup>、3.5 &#177; 1.6 mm<sup>2</sup> (P &lt; 0.01)，表明了阳和汤在延迟肺部肿瘤形成时间和降低其发生率等方面有着异于滋阴类方药的作用。</p><p>而肺癌预防的祛邪类中药多以清热解毒化痰或活血消癥为主，如清热解毒的增生平(山豆根、拳参、败酱草、白鲜皮、夏枯草、黄药子，ATB)不仅对于苯并芘诱发的野生型和抑瘤基因Ink4a/Arf缺失的肺肿瘤小鼠干预后其肺肿瘤数量降低40%，肿瘤负荷降低70% [<xref ref-type="bibr" rid="hanspub.29132-ref23">23</xref>]，而且ATB还能阻断肺鳞癌(Squamous-Cell Carcinoma, SCC)的进程，干预后肺增生区域增加2.4倍而肺SCC显著减少3.1倍(P &lt; 0.05) [<xref ref-type="bibr" rid="hanspub.29132-ref24">24</xref>]。百病生于气，气滞血瘀又是肿瘤发生的重要病机，当归赤小豆汤出自《金匮要略》，具有清利湿热、活血解毒功效，研究发现其对乌拉坦诱发小鼠肺癌模型干预22周可使致瘤率由100%下降为78%，同时荷瘤数和荷瘤体积也减少，血清学肿瘤标志物CEA水平下降(P &lt; 0.05) [<xref ref-type="bibr" rid="hanspub.29132-ref25">25</xref>]。</p><p>综上，补益类复方在肺癌发生预防体内研究中主要是通过调节免疫功能来阻碍肺癌发生，尤其是滋阴类方剂通过抑制TNF-α过度生成来抑制炎症瀑布效应 [<xref ref-type="bibr" rid="hanspub.29132-ref19">19</xref>]，进而提高体液免疫，增强巨噬细胞活性来抑制肺肿瘤的发生从而起到预防作用，此外还可调节相关癌基因的表达(如PCNA、P53)，调节与细胞生长分化等相关多种信号通路来延缓肺肿瘤的发生。而温阳类的阳和汤还可通过提高SOD、CAT、IL-2含量和活性来增强机体抗氧化功能进而阻碍肺肿瘤的发生。</p></sec><sec id="s5_2"><title>3.2. 中药单体及有效成分在肺癌预防中的作用</title><p>中药单药方面，如人参、白参以及中药单体如白藜芦醇、厚朴酚已经被证实在肺癌发生中有预防作用，可减缓癌症的进程，其机制与抗氧化及免疫调节有关。口服人参炔醇 [<xref ref-type="bibr" rid="hanspub.29132-ref26">26</xref>] 能降低KrasG12D/&#254;转基因小鼠和非小细胞肺癌移植瘤小鼠肺肿瘤的发生(P &lt; 0.05)，其通过结合Hsp90的N末端和C末端的ATP结合口袋来阻断Hsp90的功能而不增加Hsp70的表达。金茶花正丁醇提取物 [<xref ref-type="bibr" rid="hanspub.29132-ref27">27</xref>] 可使乌拉坦诱发的昆明小鼠肺癌发生率降为75.0% (模型组90.5%)，上调血清中SOD、CAT、IL-2、TNF-α含量，组织中SOD (P &lt; 0.001)、CAT (P &lt; 0.05)，表明金茶花正丁醇提取物对乌拉坦诱发小鼠肺癌的预防作用和其抗氧化和免疫调节作用相关。白藜芦醇是虎杖中的一种有效成分，在4-N-亚硝基甲基氨-1-(3-吡啶基)丁酮(NNK)诱发的A/J小鼠肺肿瘤中，白藜芦醇鼻内给药治疗可使白藜芦醇组较模型组小鼠的肿瘤数量下降27% (P = 0.0472)，肿瘤体积缩小45% (P = 0.0029) [<xref ref-type="bibr" rid="hanspub.29132-ref28">28</xref>]。NTCU诱导的雌性SWISS小鼠肺鳞癌模型中，厚朴酚能显著降低肺SCC支气管的百分比至11.0% &#177; 3.3%，模型组为24.4 &#177; 3.6% (P = 0.011)，正常支气管结构的百分比增加至38.5% &#177; 3.3%，模型组为20.5% &#177; 1.7% (P = 0.004)，表明厚朴酚能有效阻止肺SCC的进展 [<xref ref-type="bibr" rid="hanspub.29132-ref29">29</xref>]。同样的在NTCU诱发的SWISS小鼠肺鳞癌模型中，口服给药26周后发现模型组和白参(韩国产)组肺鳞癌为26.5%和9.1% (P &lt; 0.05)，与此同时肺鳞癌面积模型组和白参组分别为9.4%和1.5%，而白参组肺肿瘤呈Ki-67低染色，说明白参的对肺鳞癌发生的抑制作用是通过其抑制Ki-67和细胞增殖实现的 [<xref ref-type="bibr" rid="hanspub.29132-ref30">30</xref>]。</p></sec></sec><sec id="s6"><title>4. 中医药预防GGN的可能机制</title><p>中医药治疗肺癌的研究机制主要有：诱导细胞凋亡和周期停滞、影响细胞内相关信号通路、抑制细胞活性增殖和血管形成以及影响细胞自噬和调节免疫等方面。</p><sec id="s6_1"><title>4.1. 诱导细胞凋亡和周期停滞</title><p>没食子儿茶素没食子酸酯(Epigallocatechin Gallate, EGCG)，是绿茶中最为主要的活性茶多酚成份，在抗癌方面具有显著的作用。每天饮用10杯(120 ml/杯)的绿茶，对于女性癌症患者发病时间延缓了7.3年 [<xref ref-type="bibr" rid="hanspub.29132-ref31">31</xref>]，其机制在于调节Bax/blc-2比例、阻滞G2/M期细胞周期来发挥抗癌作用 [<xref ref-type="bibr" rid="hanspub.29132-ref32">32</xref>]。人参具有补气固脱、健脾益肺的功效，在一项276例的病例对照研究中发现人参和肺癌的比值比是0.55 [<xref ref-type="bibr" rid="hanspub.29132-ref33">33</xref>]，其所含的多种达马烷型皂苷 [<xref ref-type="bibr" rid="hanspub.29132-ref34">34</xref>] 是人参的主要药效成分。如人参皂苷Rk3可降低NSCLC活性，抑制其增殖，下调细胞周期蛋白D1、细胞周期蛋白依赖性激酶CDK4和上调P21来诱导G1期停滞，同时诱导细胞色素c释放，这些表明Rk3诱导的细胞凋亡效应是通过死亡受体介导的线粒体依赖途径实现的 [<xref ref-type="bibr" rid="hanspub.29132-ref35">35</xref>]。类似的人参皂苷Rh2也可通过诱导细胞内活性氧(Reactive Oxygen Species, ROS)介导的内质网应激来抑制H1299细胞的增殖凋亡 [<xref ref-type="bibr" rid="hanspub.29132-ref36">36</xref>]，人参皂苷Rg18在A549细胞中介导的G1期停滞也和细胞内ROS的产生、p38、JNK和NF‑κB/p65抑制紧密相关 [<xref ref-type="bibr" rid="hanspub.29132-ref37">37</xref>]。而半枝莲 [<xref ref-type="bibr" rid="hanspub.29132-ref38">38</xref>] 对CL1-5肺癌细胞的抗癌机制也可归因于G2/M期停滞和内质网应激反应、线粒体途径和外在FAS/FASL介导通路的P38/SIRT1调节细胞凋亡。</p></sec><sec id="s6_2"><title>4.2. 影响细胞内相关信号通路</title><p>半枝莲或莲甲散结方 [<xref ref-type="bibr" rid="hanspub.29132-ref39">39</xref>] 在A549、H460、H1650和H1975肺癌细胞系中可能通过P53依赖或独立通路发挥细胞毒性作用。近年来关注颇多的姜黄素研究中发现，其可通过调节STAT3通路抑制NCI-H292肺癌细胞增殖 [<xref ref-type="bibr" rid="hanspub.29132-ref40">40</xref>]，还可通过PI3K/Akt/mTOR [<xref ref-type="bibr" rid="hanspub.29132-ref41">41</xref>]、Wnt/β-catenin通路 [<xref ref-type="bibr" rid="hanspub.29132-ref42">42</xref>] 诱导肺腺癌A549细胞的凋亡。此外，槲寄生中提取的姜黄素类EB30 [<xref ref-type="bibr" rid="hanspub.29132-ref43">43</xref>] (1,7-bis(4-hydroxyphenyl)-1,4-heptadien-3-one)、峨参中提取的峨参内酯 [<xref ref-type="bibr" rid="hanspub.29132-ref44">44</xref>]、绿茶中的EGCG [<xref ref-type="bibr" rid="hanspub.29132-ref45">45</xref>] 发现均可通过PI3K/Akt信号通路诱发肺癌细胞凋亡。而抗肿瘤常用中药夏枯草中提取的齐墩果酸(Oleanolic Acid)同样可以下调Bcl-2和上调Bax来诱导肺腺癌细胞凋亡 [<xref ref-type="bibr" rid="hanspub.29132-ref46">46</xref>]。</p></sec><sec id="s6_3"><title>4.3. 抑制细胞活性、增殖和血管形成</title><p>中药通过抑制肺癌细胞活性和增殖的作用，影响肿瘤血管的形成可以有效阻断癌前病变的发生。半枝莲在A549、H460、H1650和H1975细胞株中显著抑制其活性 [<xref ref-type="bibr" rid="hanspub.29132-ref39">39</xref>]，姜黄素对NCI-H292 [<xref ref-type="bibr" rid="hanspub.29132-ref40">40</xref>]、A549 [<xref ref-type="bibr" rid="hanspub.29132-ref41">41</xref>] 和NCI-H460 [<xref ref-type="bibr" rid="hanspub.29132-ref47">47</xref>] 细胞株也表现出了明显的抑制作用，而人参稀有皂苷组分和紫杉醇配比为4:6时，对A549细胞增殖的抑制作用等效于同剂量的紫杉醇 [<xref ref-type="bibr" rid="hanspub.29132-ref48">48</xref>]。体内研究表明，半枝莲对Calu-3皮下移植瘤 [<xref ref-type="bibr" rid="hanspub.29132-ref49">49</xref>]，EGCG对荷瘤裸鼠A549肿瘤 [<xref ref-type="bibr" rid="hanspub.29132-ref50">50</xref>] 等都具有不同程度的抑瘤效应。血管内皮细胞生长因子(Vascular Endothelial Growth Facotoe, VEGF) [<xref ref-type="bibr" rid="hanspub.29132-ref51">51</xref>] 在肿瘤血管形成中占据着重要作用，半枝莲 [<xref ref-type="bibr" rid="hanspub.29132-ref52">52</xref>]、姜黄素等已有研究证实抑制VEGF分泌，如姜黄素对肺癌A549细胞亚群侧群(SP)和非SP(NSP)细胞的实验中可发现 [<xref ref-type="bibr" rid="hanspub.29132-ref53">53</xref>]，其可下调Notch和HIF-1 mRNA的表达，抑制VEGF和NF-κB的表达来抑制肺癌生长。</p></sec><sec id="s6_4"><title>4.4. 细胞自噬及免疫机制</title><p>自噬是维持组织和细胞正常形态的一种重要的分子进程，但自噬不仅与肺癌的发生进展紧密相关，亦可抑制肿瘤进展。朱湘亮等 [<xref ref-type="bibr" rid="hanspub.29132-ref54">54</xref>] 研究发现，鸦胆子油乳可促进自噬进程，并抑制A549细胞增殖迁移而起到抗肿瘤的作用。其他如半枝莲 [<xref ref-type="bibr" rid="hanspub.29132-ref38">38</xref>]、厚朴酚 [<xref ref-type="bibr" rid="hanspub.29132-ref55">55</xref>] 等均可通过诱导保护性自噬促进肺癌细胞凋亡。此外，免疫逃逸机制在肺癌的发生发展中发挥着重要作用，姜黄素可以增加肺癌患者的外周免疫系统的TH1水平降低Tregs水平 [<xref ref-type="bibr" rid="hanspub.29132-ref56">56</xref>]。夏枯草对C57BL/6lewis肺癌小鼠干预时发现夏枯草多糖P32可以增加小鼠胸腺指数和脾脏指数暗示其可能存在的免疫调节作用 [<xref ref-type="bibr" rid="hanspub.29132-ref57">57</xref>]。</p></sec></sec><sec id="s7"><title>5. 中医药对驱动基因突变型的影响</title><p>GGN人群中也有着类似于肺腺癌患者的驱动基因的突变，近些年中药干预具有基因突变型细胞系也有一些成效。人参皂苷Rg3对A549细胞的干预中，通过增加酪氨酸1045和丝氨酸1046/1047的磷酸化来下调EGFR [<xref ref-type="bibr" rid="hanspub.29132-ref58">58</xref>]，半枝莲和莲甲散结方在A549、H460、H1650中显著抑制EGFR基因和蛋白表达 [<xref ref-type="bibr" rid="hanspub.29132-ref39">39</xref>]，厚朴酚在EGFR过度表达的肺腺癌细胞中表现出抗增殖、促凋亡作用 [<xref ref-type="bibr" rid="hanspub.29132-ref59">59</xref>]。泛素激活酶E1 (Ubiquitin-Activating Enzyme E1-Like, UBE1L)的失活和EGFR突变是肺腺癌发生的早期事件，研究表明 [<xref ref-type="bibr" rid="hanspub.29132-ref60">60</xref>] 姜黄素能降低A549细胞中EGFR的表达水平并调节下游信号inHBR细胞表达UBE1L，通过EGFR泛素化诱导EGFR蛋白降解。半枝莲多聚糖(PSB)干预有Her2突变的Calu-3细胞时发现 [<xref ref-type="bibr" rid="hanspub.29132-ref49">49</xref>]，其在体外能有效抑制细胞增殖和Her2磷酸化，通过抑制Her2途径来抑制肿瘤血管的生成。厚朴酚干预KRAS突变型的NSCLC细胞系时，可依赖于AMPK-mTOR信号通路通过诱导G1期停滞和细胞凋亡从而抑制KRAS突变型的肺癌细胞。厚朴酚处理后的KRAS突变型肺癌细胞中的Sirt3显著上调，导致了其目标基因Hif-1a的不稳定，说明厚朴酚的抗癌作用和Sirt3/Hif-1a相关联 [<xref ref-type="bibr" rid="hanspub.29132-ref61">61</xref>]。</p></sec><sec id="s8"><title>6. 问题与展望</title><p>GGN作为早期肺癌的非特异性表现，已证实与肺腺癌的发生紧密联系，20%~40% [<xref ref-type="bibr" rid="hanspub.29132-ref62">62</xref>] 乃至63% [<xref ref-type="bibr" rid="hanspub.29132-ref63">63</xref>] 的GGN被报道为恶性，而现有针对GGN的诊治对策尚有不足，同时多发GGN表现的遗传异质性使得临床处理更为棘手。笔者思考从中医药干预以GGN为表现的早期肺癌的角度出发梳理至今中药治疗早期肺癌应用进展，有如下几点结论：一是现有文献已证明中药单体及复方可在体内、外实验中逆转肺癌发生进程，发挥预防肺癌的作用，呈现出成分多、靶点多的特点，其机制初步表明与抗炎、抗氧化以及免疫调节有关；二是由于GGN的诊断仍不明确，评价指标及疗效评价指标难以抉择，因此医学伦理要求下的治疗干预难以实施，且因GGN进展缓慢所致的较长干预时间等原因使得开展GGN的中医药临床研究存在一定困难；三是现有中医药预防肺癌动物实验多仅关注其预防疗效，忽视其安全性问题，虽然如金花茶正丁醇提取物对乌拉坦诱发肺癌小鼠体重影响与对照组相比无显著性差异，胸腺、肺基本无变化，脾脏、肝脏稍缩小，但目前还需要更多实验证实中医药作为长期干预用药的安全性，这将是中医药走向临床肺癌预防用药治疗不可回避的问题。而目前尚无中医药干预肺磨玻璃结节的临床研究，肺结节虚痰挟瘀成窠囊的特点使其胶着难化，中医治疗肺磨玻璃结节个案罕有缩小病例。至今中医在诊治肺磨玻璃结节患者时，多基于风险评估和积极随访的前提下进行，由经验丰富的放射科医生评估，若其恶性度较高，往往推荐手术治疗，若其风险较低则可依据中医整体观念和辨证论治的治则对有不适症状和心理负担较重的患者进行整体调理和心理疏导，同时根据中医体质对病邪的易感性、从化性特点，整体矫正患者阴阳失衡体质偏颇的病理状态，改善其免疫微环境土壤，达到稳定病灶延缓发展的作用。</p><p>综上，中医药在早期肺癌的预防中具有独特可见的优势，其多途径、多靶点的抗肿瘤作用机制仍有待进一步深入研究，中医药干预以GGN为表现的早期肺癌的临床研究及作用值得探索。</p></sec><sec id="s9"><title>基金项目</title><p>上海市教委高校“高峰高原学科建设”项目(2015-2017)；上海市科委项目(No. 16401970700)“综合康复方案对肺癌术后患者生活质量及远期生存影响的临床研究”；上海市中医药科技创新项目“基于移动互联网构建恶性肿瘤患者中医药治疗健康管理平台”(No. ZYKC201601020)；上海市促进市级医院临床技能与临床创新能力三年行动计划项目“益气养阴解毒方联合吉非替尼治疗19Del与21L858R突变的晚期肺腺癌临床研究”(No. 16CR1036B)。</p></sec><sec id="s10"><title>文章引用</title><p>肖晓宇,焦丽静,李惠民,许 玲. 中医药在以肺磨玻璃结节为特征的早期肺癌中应用进展Progress in the Application of Traditional Chinese Medicine in Early Stage Lung Cancer Characterized by Pulmonary Ground Glass Nodules[J]. 中医学, 2019, 08(02): 111-119. https://doi.org/10.12677/TCM.2019.82021</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.29132-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Chen, W.Q., Zheng, R.S., Baade, P.D., et al. (2016) Cancer Statistics in China, 2015. A Cancer Journal for Clinicians, 66, 115-132. &lt;br&gt;https://doi.org/10.3322/caac.21338</mixed-citation></ref><ref id="hanspub.29132-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Duann, C.W., Hung, J.J., Hsu, P.K., et al. (2013) Surgical Outcomes in Lung Cancer Presenting as Ground-Glass Opacities of 3 cm or Less: A Review of 5 Years Experience. Journal of the Chinese Medical Association, 76, 693-697. 
&lt;br&gt;https://doi.org/10.1016/j.jcma.2013.08.005</mixed-citation></ref><ref id="hanspub.29132-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Pedersen, J.H., Saghir, Z., Wille, M.M., et al. (2016) Ground-Glass Opacity Lung Nodules in the Era of Lung Cancer Screening: Radiology, Pathology, and Clinical Management. Lung Cancer, 30, 266-274.</mixed-citation></ref><ref id="hanspub.29132-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Scholten, E.T., Jacobs, C., van Ginneken, B., et al. (2013) Computer-Aided Segmentation and Volumetry of Artificial Ground-Glass Nodules at Chest CT. American Journal of Roentgenology, 201, 295-300.  
&lt;br&gt;https://doi.org/10.2214/AJR.12.9640</mixed-citation></ref><ref id="hanspub.29132-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Hiramatsu, M., Inagaki, T., Inagaki, T., et al. (2008) Pulmonary Ground-Glass Opacity (GGO) Lesion-Large Size and a History of Lung Cancer Are Risk Factors for Growth. Journal of Thoracic Oncology, 3, 1245-1250. 
&lt;br&gt;https://doi.org/10.1097/JTO.0b013e318189f526</mixed-citation></ref><ref id="hanspub.29132-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Cheng, Z.H., Shan, F., Yang, Y.S., et al. (2017) CT Characteristics of Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: A Systematic Review and Meta-Analysis. BioMed Central Medical Imaging, 17, 1-10.</mixed-citation></ref><ref id="hanspub.29132-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Wang, T.T., Zhang, T., Han, X.X., et al. (2015) Impact of the International Association for the Study of Cancer/American Thoracic Society/European Respiratory Society Classification of Stage I A Adenocarcinoma of the Lung: Correlation between Computed Tomography Images and EGFR and KRAS Gene Mutations. Experimental and Therapeutic Medicine, 9, 2095-2103. &lt;br&gt;https://doi.org/10.3892/etm.2015.2422</mixed-citation></ref><ref id="hanspub.29132-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Chung, J.-H., Che, G., Jheon, S., et al. (2009) Epidermal Growth Factor Receptor Mutation and Pathologic-Radiologic Correlation between Multiple Lung Nodules with Ground-Glass Opacity Differentiates Multicentric Origin from Imtrapulmonary Spread. Journal of Thoracic Oncology, 4, 1490-1495. 
&lt;br&gt;https://doi.org/10.1097/JTO.0b013e3181bc9731</mixed-citation></ref><ref id="hanspub.29132-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Liu, M., He, W.-X., Song, N., et al. (2016) Discrepancy of Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinoma Presenting as Multiple Ground-Glass Opacities. European Journal of Cardio-Thoracic Surgery, 50, 909-913. &lt;br&gt;https://doi.org/10.1093/ejcts/ezw113</mixed-citation></ref><ref id="hanspub.29132-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">MacMahon, H., Naidich, D.P., Goo, J.M., et al. (2017) Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleiscchner Society 2017. Radiology, 284, 228-243. 
&lt;br&gt;https://doi.org/10.1148/radiol.2017161659</mixed-citation></ref><ref id="hanspub.29132-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Chang, B., Hwang, J.H., Choi, Y.H., et al. (2013) Natural History of Pure Ground-Glass Opacity Lung Nodules Detected by Low Dose CT Scan. Chest, 143, 172-178. &lt;br&gt;https://doi.org/10.1378/chest.11-2501</mixed-citation></ref><ref id="hanspub.29132-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">付金花, 陈武飞, 滑炎卿. 倍增时间在磨玻璃结节随访中的应用价值[J]. 临床放射学杂志,2017, 36(6): 886-888.</mixed-citation></ref><ref id="hanspub.29132-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Kakinuma, R., Noguchi, M., Ashizawa, K., et al. (2016) Natural History of Pulmonary Subsolid Nodules: A Prospective Multicenter Study. Journal of Thoracic Oncology, 11, 1012-1028. &lt;br&gt;https://doi.org/10.1016/j.jtho.2016.04.006</mixed-citation></ref><ref id="hanspub.29132-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">朱克俭, 张亚利, 欧阳剑虹, 等. 保肺饮预防肺癌的临床流行病学研究[J]. 中国中医药科技, 1997, 4(6): 332-333.</mixed-citation></ref><ref id="hanspub.29132-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">孙兆泉, 朱克俭, 刘礼意. 保肺饮对诱生肺癌大鼠的影响[J]. 中国中西医结合外科杂志, 1998, 4(4): 198-200.</mixed-citation></ref><ref id="hanspub.29132-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">谭小宁, 刘天舒, 王红梅. 保肺饮对肺癌细胞EMT的作用及机制研究[J]. 湖南中医杂志, 2016, 32(11): 159-160.</mixed-citation></ref><ref id="hanspub.29132-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">郭慧君, 朱金华, 柳招红, 等. 六味地黄丸在肺癌发生早期对TNF-α和PCNA的影响[J]. 江西中医药大学学报, 2017, 29(3): 90-93.</mixed-citation></ref><ref id="hanspub.29132-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">李惠, 金亚宏, 姜延良. 六味地黄汤对小鼠诱发性肺腺瘤P53基因表达的影响[J]. 中国实验方剂学杂志, 1997, 3(3): 17-19.</mixed-citation></ref><ref id="hanspub.29132-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">郭慧君, 朱金华, 刘春花, 等. 不同滋阴中药对小鼠诱发性肺肿瘤发生及抗肿瘤免疫能力的影响[J]. 中国实验方剂学杂志, 2012, 18(13): 226-229.</mixed-citation></ref><ref id="hanspub.29132-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">孙昊鑫, 余世平, 朱金华, 等. 二冬膏对乌拉坦诱导肺肿瘤模型鼠TNF-α､IL-10､TGF-β1及肿瘤发生的影响[J]. 中药药理与临床, 2015, 31(6): 7-10.</mixed-citation></ref><ref id="hanspub.29132-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">熊秋迎, 朱金华, 孙昊鑫, 等. 清燥救肺汤对乌拉坦诱导肺癌模型树TGF-β､Smad2和p38MARK的影响[J]. 中药药理与临床, 2018, 34(3): 14-17.</mixed-citation></ref><ref id="hanspub.29132-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">杜钢军, 林海红, 许启泰, 等. 阳和汤对乌拉坦诱导小鼠肺癌的动态影响[J]. 时珍国医国药, 2008, 19(5): 1151-1153.</mixed-citation></ref><ref id="hanspub.29132-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Z., Wang, Y., Yao, R., et al. (2004) Cancer Chemopreventive Activity of Chinese Herbs (Antitumor B) in Mouse Lung Tumor Models. Oncogene, 23, 3841-3850. &lt;br&gt;https://doi.org/10.1038/sj.onc.1207496</mixed-citation></ref><ref id="hanspub.29132-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y., Zhang, Z., Garbow, J.R., et al. (2009) Chemoprevention of Lung Squamous Cell Carcinoma in Mice by a Mixture of Chinese Herbs. Cancer Prevention Research, 2, 634-640.  
&lt;br&gt;https://doi.org/10.1158/1940-6207.CAPR-09-0052</mixed-citation></ref><ref id="hanspub.29132-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">杜振华, 姚静静, 李自波, 等. 当归赤小豆汤对乌拉坦诱导小鼠肺癌的预防作用[J]. 河南大学学报(医学版), 2017, 36(3): 153-155.</mixed-citation></ref><ref id="hanspub.29132-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Le, H.T., Nguyen, H.T., Min, H.-Y., et al. (2018) Panaxynol, a Natural Hsp90 Inhibitor, Effectively Targets both Lung Cancer Stem and Non-Stem Cells. Cancer Letters, 412, 297-307. &lt;br&gt;https://doi.org/10.1016/j.canlet.2017.10.013</mixed-citation></ref><ref id="hanspub.29132-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">孔桂菊, 杜鸿志, 袁胜涛, 等. 金花茶正丁醇提取物对乌拉坦诱导小鼠肺癌作用研究[J]. 亚太传统医药, 2015, 11(21): 4-7.</mixed-citation></ref><ref id="hanspub.29132-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Monteillier, A., Voisin, A., Furrer, P., et al. (2018) Intranasal Administration of Resveratrol Successfully Prevents Lung Cancer in A/J Mice. Scientific Reports, 8, Article No. 14257. &lt;br&gt;https://doi.org/10.1038/s41598-018-32423-0</mixed-citation></ref><ref id="hanspub.29132-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Pan, J., Zhang, Q., Liu, Q., et al. (2014) Honokiol Inhibits Lung Tumorigenesis through Inhibition of Mitochondrial Function. Cancer Prevention Research, 7, 1149-1159. &lt;br&gt;https://doi.org/10.1158/1940-6207.CAPR-14-0091</mixed-citation></ref><ref id="hanspub.29132-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Pan, J., Zhang, Q., Li, K., et al. (2014) Chemoprevention of Lung Squamous Cell Carcinoma by Ginseng. Cancer Prevention Research, 6, 530-540. &lt;br&gt;https://doi.org/10.1158/1940-6207.CAPR-12-0366</mixed-citation></ref><ref id="hanspub.29132-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Nakachi, K., Matsuyama, S., Miyake, S., et al. (2000) Preventive Effects of Drinking Green Tea on Cancer and Cardiovascular Disease: Epidemiological Evidence for Multiple Targeting Prevention. Biofactors, 13, 49-54.  
&lt;br&gt;https://doi.org/10.1002/biof.5520130109</mixed-citation></ref><ref id="hanspub.29132-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Huang, J., Chen, S., Shi, Y., et al. (2017) Epigallocatechin Gallate from Green Tea Exhibits Potent Anticancer Effects in A549 Non-Small Lung Cancer Cells by Inducing Apoptosis, Cell Cycle Arrest and Inhibition of Cell Migaration. Journal of Buon, 22, 1422-1427.</mixed-citation></ref><ref id="hanspub.29132-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Jin, X., Che, D., Zhang, Z., et al. (2016) Ginseng Consumption and Risk of Cancer: A Meta-Analysis. Journal of Ginseng Research, 40, 269-277. &lt;br&gt;https://doi.org/10.1016/j.jgr.2015.08.007</mixed-citation></ref><ref id="hanspub.29132-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Xu, Q., Fang, X. and Chen, D. (2003) Pharmacokinetics and Bioavailability of Ginsenoside Rb1 and Rg1 from Panax Notoginseng in Rats. Journal of Ethnopharmacology, 84, 187-192. &lt;br&gt;https://doi.org/10.1016/S0378-8741(02)00317-3</mixed-citation></ref><ref id="hanspub.29132-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Duan, Z., Deng, J., Dong, Y., et al. (2017) Anticancer Effects of Ginsenoside Rk3 on Non-Small Cell Lung Cancer Cells: In Vitro and in Vivo. Royal Society of Chemistry, 8, 3723-3736.</mixed-citation></ref><ref id="hanspub.29132-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Ge, G., Yan, Y. and Cai, H. (2017) Ginsenoside Rh2 Inhibited Proliferation by Inducing ROS Mediated ER Stress Dependent Apoptosis in Lung Cancer Cell. Biological and Pharmaceutical Bulletin, 40, 2117-2124.  
&lt;br&gt;https://doi.org/10.1248/bpb.b17-00463</mixed-citation></ref><ref id="hanspub.29132-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Leem, D., Shin, J., Kim, K., et al. (2018) Dammarane-Type Triterpene Ginsenside-Rg18 Inhibits Human Non-Small Cell Lung Cancer A549 Cell Proliferation via G1 Phase Arrest. Oncology Letters, 15, 6043-6049.</mixed-citation></ref><ref id="hanspub.29132-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Chen, C., Kao, C., Chiu, M., et al. (2017) The Anti-Cancer Effects and Mechanisms of Scutellaria barbata D.Don on CL1-5 Lung Cancer Cells. Oncotarget, 8, 109340-109357. &lt;br&gt;https://doi.org/10.18632/oncotarget.22677</mixed-citation></ref><ref id="hanspub.29132-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Q., Acharaya, N., Liu, Z., et al. (2018) Enhanced Anti-cancer Effects of Scutellaria barbata D.Don in Combination with Traditional Chinese Medicine Components on Non-Small Cell Lung Cancer Cells. Journal of Ethnopharmacology, 217, 140-151. &lt;br&gt;https://doi.org/10.1016/j.jep.2018.02.020</mixed-citation></ref><ref id="hanspub.29132-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Tang, L., Liu, J., Zhu, L., et al. (2018) Curcumin Inhibits Growth of Human NCI-H292 Lung Squamous Cell Carcinoma Cells by Increasing Foxa2 Expression. Frontiers in Pharmacology, 9, 1-9.  
&lt;br&gt;https://doi.org/10.3389/fphar.2018.00060</mixed-citation></ref><ref id="hanspub.29132-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Liu, F., Gao, S., Yang, Y., et al. (2018) Anitumor Activity of Curcumin by Modulation of Apoptosis and Autophagy in Human Lung Cancer A549 Cells Throung Inhibiting PI3K/AKt/mTOR Pathway. Oncology Reports, 39, 1523-1531.</mixed-citation></ref><ref id="hanspub.29132-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J.Y., Wang, X., Wang, X.J., et al. (2018) Curcumin Inhibits the Growth via Wnt/β-Catenin Pathway in Non-Small-Cell Lung Cancer Cells. European Review for Medical and Pharmacological Sciences, 22, 7492-7499.</mixed-citation></ref><ref id="hanspub.29132-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Fan, J., Wu, M., Wang, J., et al. (2018) 1,7-Bis(4-hydroxyphenyl)-1,4-heptadien-3-one Induces Lung Cancer Cell Apoptosis via the PI3K/Akt and ERK1/2 Pathways. Journal of Cellular Physiology, 1-14.</mixed-citation></ref><ref id="hanspub.29132-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Park, B., Lee, S.A., Moon, S.M., et al. (2018) Anthricin-Induced Caspase-Dependent Apoptosis through IGF1R/PI3K/AKT Pathway Inhibition in A549 Human Non-Small Lung Cancer Cells. Oncology Reports, 39, 2769-2776.</mixed-citation></ref><ref id="hanspub.29132-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Gu, J.J., Qiao, K.S., Sun, P., et al. (2018) Study of EGCG Induced Apoptosis in Lung Cancer Cells by Inhibiting PI3K/Akt Signaling Pathway. European Review for Medical and Pharmacological Sciences, 22, 4557-4563.</mixed-citation></ref><ref id="hanspub.29132-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Feng, L., Au-yeung, W., Xu, Y., et al. (2017) Oleanolic Acid from Prunella vulgaris L. Induces SPC-A-1 Cell Line Appptosis via Regulation of Bax, Bad and Bcl-2 Expression. Asian Pacific Journal of Cancer Prevention, 12, 403-408.</mixed-citation></ref><ref id="hanspub.29132-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Xu, X. and Zhu, Y. (2017) Curcumin Inhibits Human Non-Small Cell Lung Cancer Xenografts by Targeting STAT3 Pathway. American Journal of Translational Research, 9, 3633-3641.</mixed-citation></ref><ref id="hanspub.29132-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">杨蕾, 张振海, 贾晓斌. 人参稀有皂苷组分联合紫杉醇治疗A549肺癌的实验研究[J]. 中国中药杂志, 2018, 43(7): 1146-1452.</mixed-citation></ref><ref id="hanspub.29132-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Yang, J., Yang, G., Hou, G., et al. (2015) Scutellaria barbata D.Don Polysaccharides Inhibit the Growth of Calu-3 Xenograft Tumors via Suppression of the Her2 Pathway and Angipgenesis. Oncology Letters, 9, 2721-2725.  
&lt;br&gt;https://doi.org/10.3892/ol.2015.3127</mixed-citation></ref><ref id="hanspub.29132-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">He, L., Zhang, E., Shi, J., et al. (2013) (-)-Epigallocatechin-3-Gallate Inhibits Human Papillomavirus (HPV)-16 Oncoprotein-Induced Angiogenesis in Non-Small Cell Lung Cancer Cells Bu Targeting HIF-1α. Cancer Chemotherapy, 71, 713-725. &lt;br&gt;https://doi.org/10.1007/s00280-012-2063-z</mixed-citation></ref><ref id="hanspub.29132-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Liu, S., Xin, X., Hua, T., et al. (2016) Efficacy of Anti-VEGF/VEGFR Agents on Animal Models of Endometriosis: A Systematic Review and Meta-Analysis. PLoS ONE, 11, e0166658.</mixed-citation></ref><ref id="hanspub.29132-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Shiau, A., Shen, Y., Hsieh, J., et al. (2014) Scutellaria barbata Inhibits Angiofenesis through Downregulation of HIF-1α in Lung Tumor. Environmental Toxicology, 29, 363-370. &lt;br&gt;https://doi.org/10.1002/tox.21763</mixed-citation></ref><ref id="hanspub.29132-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">Li, X., Ma, S., Yang, P., et al. (2018) Anticancer Effects of Curcumin on Nude Mice Bearing Lung Cancer A549 Cell Subsets SP and NSP Cells. Oncology Letters, 16, 6756-6762. &lt;br&gt;https://doi.org/10.3892/ol.2018.9488</mixed-citation></ref><ref id="hanspub.29132-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">朱湘亮, 潘频华. 鸦胆子油乳对人非小细胞肺癌A549细胞增殖､迁移和自噬的影响及机制[J]. 中南大学学报(医学版), 2018, 43(11): 1202-1208.</mixed-citation></ref><ref id="hanspub.29132-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Yang, J., Wu, W., Wen, J., et al. (2017) Liposomal Honokiol Induced Lysosomal Degradation of Hsp90 Client Proteins and Protective Autophagy in Both Gefitinib-Sensitive and Gefitinib-Resistant NSCLC Cells. Biomaterials, 141, 188-198. &lt;br&gt;https://doi.org/10.1016/j.biomaterials.2017.07.002</mixed-citation></ref><ref id="hanspub.29132-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, J., Su, C., Luo, H., et al. (2018) Curcumin Converts Foxp3+ Regulatory T Cells to T Helper 1 Cells in Patients with Lung Cancer. Journal of Cellular Biochemistry, 119, 1420-1428. &lt;br&gt;https://doi.org/10.1002/jcb.26302</mixed-citation></ref><ref id="hanspub.29132-ref57"><label>57</label><mixed-citation publication-type="other" xlink:type="simple">Feng, L., Jia, X., Shi, F., et al. (2010) Identification of Two Polysaccharides from Prunella vulgaris L. and Evaluation on Their Anti-Lung Adenocarcinoma Activity. Molecules, 15, 5093-5103. &lt;br&gt;https://doi.org/10.3390/molecules15085093</mixed-citation></ref><ref id="hanspub.29132-ref58"><label>58</label><mixed-citation publication-type="other" xlink:type="simple">Joo, E.J., Chun, J., Han, Y.W., et al. (2015) Novel Roles of Ginsenoside Rg3 in Apoptosis through Downregulation of Epidermal Growth Factor Receptor. Chemico-Biological Interactions, 233, 25-34.  
&lt;br&gt;https://doi.org/10.1016/j.cbi.2015.03.016</mixed-citation></ref><ref id="hanspub.29132-ref59"><label>59</label><mixed-citation publication-type="other" xlink:type="simple">Song, J.M., Anandharaj, A., Upadhyaya, P., et al. (2016) Honokiol Suppresses Lung Tumorigenesis by Targeting EGFR and Its Downstream Effectors. Oncotarget, 7, 57753-57769. &lt;br&gt;https://doi.org/10.18632/oncotarget.10759</mixed-citation></ref><ref id="hanspub.29132-ref60"><label>60</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, A.-P., Zhou, D.-H., Meng, X.-L., et al. (2014) Down-Regulation of Epidermal Growth Factor Receptor by Curcumin-Induced UBE1L in Human Bronchial Epithelial Cells. Journal of Nutritional Biochemistry, 25, 241-249.  
&lt;br&gt;https://doi.org/10.1016/j.jnutbio.2013.11.001</mixed-citation></ref><ref id="hanspub.29132-ref61"><label>61</label><mixed-citation publication-type="other" xlink:type="simple">Luo, L., Li, Y., Liu, Z., et al. (2017) Honokiol Induces Apoptosis, G1 Arrest, and Autopjagy in KRAS Mutant Lung Cancer Cells. Frontiers in Pharmacologh, 8, 1-11. &lt;br&gt;https://doi.org/10.3389/fphar.2017.00199</mixed-citation></ref><ref id="hanspub.29132-ref62"><label>62</label><mixed-citation publication-type="other" xlink:type="simple">Lee, H.J., Goo, J.M., Lee, C.H., et al. (2009) Predictive CT Findings of Malignancy in Ground-Glass Nodules on Thin-Section Chest CT: The Effects on Radiologist Performance. European Radiology, 19, 552-560.  
&lt;br&gt;https://doi.org/10.1007/s00330-008-1188-2</mixed-citation></ref><ref id="hanspub.29132-ref63"><label>63</label><mixed-citation publication-type="other" xlink:type="simple">Migliore, M., Fornito, M., Palazzolo, M., et al. (2018) Ground Glass Opacities Management in the Lung Cancer Screening Era. Annals of Translational Medicine, 6, 90-97. &lt;br&gt;https://doi.org/10.21037/atm.2017.07.28</mixed-citation></ref></ref-list></back></article>